Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Eli Lilly and Company & Pfizer

12 shared events · Importance 3 · Last updated Sep 04, 2026

Importance
3
Shared Events
12
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
79
Business
Eli Lilly and Company: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Pfizer: Pfizer entered the Chinese market with Xianweiying and partners with gyms for promotions. It is a newer entrant seeking market share.
Aug 24, 2026 · 6 articles
40
Domestic
Eli Lilly and Company: Eli Lilly was among the earlier drugmakers that agreed to MFN pricing, contributing to the administration's drug pricing push.
Pfizer: Pfizer was among the earlier 17 drugmakers that signed MFN deals, setting a precedent. The new agreements expand the framework to more companies.
Aug 18, 2026 · 37 articles
39
Business
Eli Lilly and Company: Central subject of the event: shares fell about 7-8% over the month on pricing and IPR&D charges despite strong Q2 beats and raised 2026 guidance. Citi's Street-high $1,600 target frames the selloff as overdone, leaving the stock as the widest analyst-implied upside in its pharma peer group.
Pfizer: Peer with only about 4.1% implied upside and Hold-skewed ratings, underscoring how Lilly stands out on analyst-implied returns within pharma.
Sep 14, 2026 · 6 articles
20
Business
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Pfizer: Pfizer's Litfulo is a competitor JAK inhibitor; positive bempikibart data may affect its market position.
Jul 13, 2026 · 6 articles
20
Regulatory
Eli Lilly and Company: Eli Lilly supported Gilead's appeal, benefiting from the ruling that protects drugmakers from duty-to-innovate claims.
Pfizer: Pfizer supported Gilead's appeal, gaining from the precedent that protects pharmaceutical innovation.
Aug 03, 2026 · 6 articles
5
Business
Eli Lilly and Company: Eli Lilly is mentioned as having a chief AI officer, but not directly impacted.
Pfizer: Pfizer is mentioned as having a chief AI officer, but not directly impacted.
Aug 11, 2026 · 7 articles
0
Business
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
0
Regulatory
Pfizer: Pfizer had previously struck a deal with the administration to rein in prices and expects United States — Medicaid discounts to result in price and margin compression next year.
Dec 19, 2025 · 7 articles
0
Business
Pfizer: Pfizer India partnered with Cipla to expand the reach of its medicines across India, while continuing to manufacture and supply the four brands involved in the agreement.
Dec 19, 2025 · 6 articles
0
Business
Feb 03, 2026 · 6 articles
0
Regulatory
Apr 02, 2026 · 23 articles
0
Business
May 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Eli Lilly and Company and Pfizer interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.